

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Pentoject Pentobarbitone Sodium 200 mg/ml Solution for Injection

2. STATEMENT OF ACTIVE SUBSTANCES

Pentobarbitone Sodium 200 mg/ml

3. PACKAGE SIZE

100ml
250ml
500ml

4. TARGET SPECIES

Dogs, cats other small animals and mink

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Dose: To effect, usually 0.4ml/kg in debilitated or elderly animals, 0.6-0.8 ml/kg in younger or more fit animals, preferably by rapid intravenous injection.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}
Once broached use within 28 days.
Once opened, use by...

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C. Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER



14. MARKETING AUTHORISATION NUMBER

Vm 32742/4033

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Pentoject Pentobarbitone Sodium 200 mg/ml Solution for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Pentobarbitone Sodium 200 mg/ml

3. TARGET SPECIES

Dogs, cats other small animals and mink

4. ROUTES OF ADMINISTRATION

Reas the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use within 28 days.

Once opened, use by...

7. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C. Protect from light.

8. NAME OF THE MARKETING AUTHORISATION HOLDER



9. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Pentoject Pentobarbitone Sodium 200 mg/ml Solution for Injection

2. Composition

Each ml contains:

Active substance:

Pentobarbitone Sodium 200 mg

Excipients

Tartrazine 1409 (E102) 0.04 mg

Clear, yellow solution.

3. Target species

Dogs, cats, other small animals and mink.

4. Indications for use

For euthanasia in dogs, cats, other small animals and mink

5. Contraindications

Contra-indications, warnings: Not for use in anaesthesia. Not for use in animals intended for human or animal consumption.

6. Special warnings

Special warnings:

For animal treatment only.

Special precautions for safe use in the target species

Use only for euthanasia.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In the event of accidental self-administration, by injection or skin absorption, seek URGENT medical attention, advising the physician of barbiturate poisoning and show the package leaflet or label.

This is a potent drug, which is toxic in man. Particular care should be taken to avoid accidental ingestion or self-injection.

In the event of accidental exposure the following actions should be taken:

Skin- Wash immediately with water and then thoroughly with soap and water.

Eyes- Wash immediately with cold water and obtain medical advice.

Ingestion- Obtain medical attention immediately. Wash out mouth. Keep warm and rest.

Accidental self-injection- Obtain URGENT medical attention advising the physician of barbiturate poisoning. Do not leave patient unattended.

Advice to physician- Maintain airways and give symptomatic and supportive treatment. This product is not sterile.

Interaction with other medicinal products and other forms of interaction:

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

Overdose:

If accidentally administered to an animal not presented for euthanasia, care should be aimed at supporting the respiratory and cardiovascular systems. Use of artificial respiration, oxygen and analeptics are appropriate.

7. Adverse events

Target species: Dogs, cats, other small animals, and mink

Undetermined frequency (cannot be estimated from the available data)	Body spasm ¹
--	-------------------------

¹ May distress observers. Very low frequency, when an appropriate dose is used and administered rapidly.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Dosage and Administration: To effect by rapid intravenous injection, usually 0.4ml/kg in debilitated or elderly animals, or 0.6-0.8ml/kg in younger or fit animals. These dosages correspond to 80mg/kg or 120-160mg/kg, respectively. The intravenous route of administration should be the route of choice if possible but alternatives such as intraperitoneal or intramuscular are available when venepuncture is difficult to achieve (e.g. in cats). In some circumstances the intrathoracic route may be used but this is usually the last resort. There is a risk of injection into the lungs, which causes coughing and distress.

Direct injection into a chamber of the heart is rapid but it may be difficult to accurately locate the heart chamber in larger dogs and repeated attempts could cause unnecessary pain and distress.

9. Advice on correct administration

To effect, usually 0.4 ml/kg in debilitated or elderly animals, or 0.6-0.8 ml/kg in younger or more fit animals. These dosages correspond to 80 mg/kg or 120-160 mg/kg, respectively. Preferably by rapid intravenous injection.

The intravenous route of administration should be the route of choice if possible but alternatives such as intraperitoneal or intramuscular are available when venepuncture is difficult to achieve (e.g. in cats). In some circumstances the intrathoracic route may be used but this is usually the last resort. There is a risk of injection into the lungs which causes coughing and distress. Direct injection into a chamber of the heart is rapid, but it may be difficult to accurately locate the heart chamber in larger dogs and repeated attempts could cause unnecessary pain and distress.

When it is predicted that euthanasia may be problematical (i.e. aggressive patients), it is recommended that premedication with an appropriate sedative be given.

10. Withdrawal periods

Not for use in animals intended for human or animal consumption.

11. Special storage conditions

Keep out of the sight and reach of children

Do not store above 25°C. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Shelf life after opening the immediate packaging 28 days.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Any unused product must be destroyed in accordance with the Misuse of Drugs Regulations (2001).

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBER AND PACK SIZES

Vm 32742/4033

Pack sizes:

100ml

250ml
500ml
Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder:
Ecuphar NV
Legeweg 157-i
8020 Oostkamp
Belgium

Manufacturer responsible for batch release:
Produlab B.V.
Forellenweg 16
Ramsdonksveer
4941SJ
The Netherlands

Local representatives and contact details to report suspected adverse reactions:

Animalcare Ltd
Moorside
Monks Cross
York, YO32 9LB
United Kingdom
Tel: +44 (0) 330 8189717
E-mail: animalcare@animalcare.co.uk

17. Other information

To be supplied only on veterinary prescription. UK authorised veterinary medicinal product.

POM-V

Gavin Hall
Approved: 31 March 2026